These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9291245)

  • 1. Potential economic impact of glycoprotein IIb-IIIa inhibitors in improving outcomes of patients with acute ischemic coronary syndromes.
    McElwee NE; Johnson ER
    Am J Cardiol; 1997 Aug; 80(4A):39B-43B. PubMed ID: 9291245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and non-ST-segment elevation acute coronary syndromes. Estimating the economic implications.
    Hillegass WB; Newman AR; Raco DL
    Pharmacoeconomics; 2001 Jan; 19(1):41-55. PubMed ID: 11252545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes.
    Boersma E
    J Am Coll Cardiol; 2007 Jan; 49(2):276; author reply 277. PubMed ID: 17222743
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis.
    Glaser R; Glick HA; Herrmann HC; Kimmel SE
    J Am Coll Cardiol; 2006 Feb; 47(3):529-37. PubMed ID: 16458131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes.
    Plosker GL; Ibbotson T
    Pharmacoeconomics; 2003; 21(12):885-912. PubMed ID: 12908844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of IIb/IIIa receptor blockade in patients with unstable angina.
    Vahanian A; Michaud P; Garbarz E
    Semin Interv Cardiol; 1999 Jun; 4(2):61-6. PubMed ID: 10473874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet glycoprotein inhibitors in patients with medically managed acute coronary syndrome: does the enthusiasm exceed the science?
    Schriger DL; Herbert ME
    Ann Emerg Med; 2001 Sep; 38(3):249-55. PubMed ID: 11524643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy.
    Roffi M; Chew DP; Mukherjee D; Bhatt DL; White JA; Moliterno DJ; Heeschen C; Hamm CW; Robbins MA; Kleiman NS; Théroux P; White HD; Topol EJ
    Eur Heart J; 2002 Sep; 23(18):1441-8. PubMed ID: 12208224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
    Rajagopal V; Lincoff AM; Cohen DJ; Gurm HS; Hu T; Desmet WJ; Kleiman NS; Bittl JA; Feit F; Topol EJ
    Am Heart J; 2006 Jul; 152(1):149-54. PubMed ID: 16824845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics, treatment and outcome of patients with non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: observations from PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrelin therapy).
    Breeman A; Mercado N; Lenzen M; van den Brand MM; Harrington RA; Califf RM; Topol EJ; Simoons ML; Boersma E;
    Cardiology; 2002; 98(4):195-201. PubMed ID: 12566649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty.
    Haase KK; Mahrholdt H; Schröder S; Baumbach A; Oberhoff M; Herdeg C; Karsch KR
    Am Heart J; 1999 Feb; 137(2):234-40. PubMed ID: 9924156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.
    Boersma E; Harrington RA; Moliterno DJ; White H; Théroux P; Van de Werf F; de Torbal A; Armstrong PW; Wallentin LC; Wilcox RG; Simes J; Califf RM; Topol EJ; Simoons ML
    Lancet; 2002 Jan; 359(9302):189-98. PubMed ID: 11812552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications.
    van Hout BA; Bowman L; Zelinger DJ; Simoons ML
    Eur Heart J; 1998 Apr; 19 Suppl D():D59-66. PubMed ID: 9597523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Determinants of treatment costs of unstable angina pectoris].
    Klepzig H; Krobot K; Flettner R; Winten G; Zeiher AM
    Z Kardiol; 1999 Apr; 88(4):261-9. PubMed ID: 10408030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease.
    Berkowitz SD
    Haemostasis; 2000; 30 Suppl 3():27-43. PubMed ID: 11182626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.
    Stone GW; Bertrand ME; Moses JW; Ohman EM; Lincoff AM; Ware JH; Pocock SJ; McLaurin BT; Cox DA; Jafar MZ; Chandna H; Hartmann F; Leisch F; Strasser RH; Desaga M; Stuckey TD; Zelman RB; Lieber IH; Cohen DJ; Mehran R; White HD;
    JAMA; 2007 Feb; 297(6):591-602. PubMed ID: 17299194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors: in the management of acute coronary syndromes.
    Bosanquet N; Jönsson B; Fox KA
    Pharmacoeconomics; 2003; 21(16):1135-52. PubMed ID: 14594436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
    Silva MA; Donovan JL; Gandhi PJ; Volturo GA
    Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications.
    Mak KH; Challapalli R; Eisenberg MJ; Anderson KM; Califf RM; Topol EJ
    Am J Cardiol; 1997 Oct; 80(8):985-8. PubMed ID: 9352964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycoprotein IIb-IIIa antagonists in percutaneous coronary interventions and acute coronary syndromes.
    Ramanathan A; Kleiman NS
    Indian Heart J; 1998 Oct; 50 Suppl 1():45-56. PubMed ID: 9824907
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.